Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 5/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 3/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 2/20 | 0.30 |
| ▸ | DAO | P14920 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2084601 | 1.00 | PDE3B (0.36) | PDE3BPDE3ARXFP1LMNAL3MBTL1 | |
| SCHEMBL2084597 | 1.00 | PDE3B (0.36) | PDE3BPDE3ARXFP1LMNAL3MBTL1 | |
| SCHEMBL2085117 | 0.70 | ADORA3 (0.39) | LMNADPP4MEN1KMT2AADORA3 | |
| SCHEMBL2085115 | 0.70 | ADORA3 (0.39) | LMNADPP4MEN1KMT2AADORA3 | |
| SCHEMBL3286320 | 0.69 | RXFP1 (0.41) | PDE3BPDE3ARXFP1LMNADPP4 | |
| SCHEMBL2084768 | 0.69 | PDE3B (0.45) | PDE3BPDE3ARXFP1LMNADPP4 | |
| SCHEMBL6644837 | 0.69 | RXFP1 (0.57) | PDE3BPDE3ARXFP1LMNADPP4 | |
| SCHEMBL2085663 | 0.66 | RXFP1 (0.34) | PDE3BPDE3ARXFP1LMNAL3MBTL1 | |
| SCHEMBL2082194 | 0.65 | KDM4E (0.48) | RXFP1LMNADPP4MEN1PABPC1 | |
| SCHEMBL2313749 | 0.63 | CYP3A4 (0.47) | PDE3BPDE3ARXFP1LMNAADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163935-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090312383-A1 | Fused Heterocyclic Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312383-A1 | Fused Heterocyclic Compounds | NPY4R, CRHR1, CNR1 | PDE3B 2049/4885PDE3A 2738/4885RXFP1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.